|
| 36831348 | Characterization of the Tumor Microenvironment in Jaw Osteosarcomas, towards Prognostic Markers and New Therapeutic Targets. | Cancers (Basel) | 2023 |
| 37719019 | MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells. | Front Oncol | 2023 |
| 37752913 | Ewing sarcoma from molecular biology to the clinic. | Front Cell Dev Biol | 2023 |
| 35337159 | Tumor Suppressive Role of miR-342-5p and miR-491-5p in Human Osteosarcoma Cells. | Pharmaceuticals (Basel) | 2022 |
| 35530297 | Signature of the vascular tumor microenvironment as a marker of the therapeutic response to doxorubicin in a preclinical model of osteosarcoma. | Am J Cancer Res | 2022 |
| 36428719 | TRAIL-Based Therapies Efficacy in Pediatric Bone Tumors Models Is Modulated by TRAIL Non-Apoptotic Pathway Activation via RIPK1 Recruitment. | Cancers (Basel) | 2022 |
| 35326631 | Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas. | Cancers (Basel) | 2022 |
| 34062831 | ICG-001, an Inhibitor of the β-Catenin and cAMP Response Element-Binding Protein Dependent Gene Transcription, Decreases Proliferation but Enhances Migration of Osteosarcoma Cells. | Pharmaceuticals (Basel) | 2021 |
| 33498676 | Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment? | Cancers (Basel) | 2021 |
| 34944050 | LIM Kinases in Osteosarcoma Development. | Cells | 2021 |
| 34885102 | Pyridazinone Derivatives Limit Osteosarcoma-Cells Growth In Vitro and In Vivo. | Cancers (Basel) | 2021 |
| 34765560 | Involvement of the TGF-β Signaling Pathway in the Development of YAP-Driven Osteosarcoma Lung Metastasis. | Front Oncol | 2021 |
| 34571917 | Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619. | Cells | 2021 |
| 34678225 | Ubiquitin-specific proteases as therapeutic targets in paediatric primary bone tumours? | Biochem Pharmacol | 2021 |
| 32164350 | Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers? | Cancers (Basel) | 2020 |
| 33228057 | Sonic Hedgehog Signature in Pediatric Primary Bone Tumors: Effects of the GLI Antagonist GANT61 on Ewing's Sarcoma Tumor Growth. | Cancers (Basel) | 2020 |
| 33113487 | Osteosarcoma of the jaws: An overview of the pathophysiological mechanisms. | Crit Rev Oncol Hematol | 2020 |
| 33419295 | The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth. | Cancers (Basel) | 2020 |
| 32859065 | Antagonistic Functions of Connexin 43 during the Development of Primary or Secondary Bone Tumors. | Biomolecules | 2020 |
| 32110934 | SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression. | Cells | 2020 |
| 32326444 | The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem. | Cells | 2020 |
| 31045351 | 12b80 - Hydroxybisphosphonate Linked Doxorubicin: Bone Targeted Strategy for Treatment of Osteosarcoma. | Bioconjug Chem | 2019 |
| 31717935 | Epinephrine Infiltration of Adipose Tissue Impacts MCF7 Breast Cancer Cells and Total Lipid Content. | Int J Mol Sci | 2019 |
| 31604924 | Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression. | Nat Commun | 2019 |
| 31260659 | Genetically-achieved disturbances to the expression levels of TNFSF11 receptors modulate the effects of zoledronic acid on growing mouse skeletons. | Biochem Pharmacol | 2019 |
| 31370265 | New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies? | Int J Mol Sci | 2019 |
| 30813941 | Jaw osteosarcoma models in mice: first description. | J Transl Med | 2019 |
| 29190507 | Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. | Eur J Cancer | 2018 |
| 30093324 | In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models. | Cytotherapy | 2018 |
| 30413057 | Maternal RANKL Reduces the Osteopetrotic Phenotype of Null Mutant Mouse Pups. | J Clin Med | 2018 |
| 29761075 | Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment. | Front Oncol | 2018 |
| 29323712 | Paradoxical side effects of bisphosphonates on the skeleton: What do we know and what can we do? | J Cell Physiol | 2018 |
| 28932633 | CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. | Oncoimmunology | 2017 |
| 29221170 | Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept. | Oncotarget | 2017 |
| 29218254 | Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling. | Am J Cancer Res | 2017 |
| 28707014 | Doxycycline and its quaternary ammonium derivative for adjuvant therapies of chondrosarcoma. | Cancer Chemother Pharmacol | 2017 |
| 27006472 | Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1. | Oncotarget | 2016 |
| 27863724 | [Which approach of therapeutic education (TE) for adolescents and young adults with cancer? Experience from the TE working group of "Go-AJA"]. | Bull Cancer | 2016 |
| 27827889 | TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression. | J Clin Med | 2016 |
| 27558972 | TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models. | Int J Cancer | 2016 |
| 27324280 | Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. | Lancet Oncol | 2016 |
| 27573424 | Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept. | Mol Cancer Ther | 2016 |
| 27519659 | Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw. | J Craniomaxillofac Surg | 2016 |
| 27315524 | The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. | Clin Sarcoma Res | 2016 |
| 27152244 | L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. | Am J Cancer Res | 2016 |
| 26910666 | Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells. | Plast Reconstr Surg | 2016 |
| 26802024 | The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. | Oncotarget | 2016 |
| 26712686 | Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression. | Clin Cancer Res | 2016 |
| 24961790 | BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. | Int J Cancer | 2015 |
| 26779435 | Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma. | Front Oncol | 2015 |